EQS-Adhoc: Eckert & Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

EQS-Ad-hoc: Eckert Ziegler Strahlen- und Medizintechnik AG / Key word(s): Joint Venture
Eckert Ziegler Establishes German-Chinese Joint Venture with DC Pharma for the Production of Radioisotopes

14-Nov-2023 / 12:04 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Berlin, 14.11.2023. Eckert Ziegler (ISIN DE0005659700) strengthens its competitive position in the growth market of China and today signed a 50:50 joint venture agreement with the Chinese pharmaceutical company DongCheng Pharma (DC Pharma).

Eckert Ziegler will benefit from the cooperation between the two companies above all at its production site in Jintan near Shanghai. Here, the radioisotopes urgently needed for cancer diagnostics and therapy on the growing Chinese market shall be produced and commercialized.

DC Pharma invests € 20 million in the EZAG subsidiary Qi Kang Medical Technology (Changzhou) Co., Ltd. by way of a capital increase and will subsequently hold 50% of the shares.

The joint venture will complete the production facility currently under construction in Jintan and start the production of cyclotron-based isotopes in a first phase. In a second phase, further production lines for radioisotopes such as Lu-177 are to follow.

DC Pharma is one of the leading radiopharmaceutical companies in China with sales of 498 million US$ or 3.6 billion CNY (2022). With its market position, experience in production and sales, it is the ideal partner for Eckert Ziegler.

Contact:
Eckert Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com

End of Inside Information

14-Nov-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English Company: Eckert Ziegler Strahlen- und Medizintechnik AG Robert-Rössle-Str.10 13125 Berlin Germany Phone: +49 30 941084-138 Fax: +49 30 941084-112 E-mail: karolin.riehle@ezag.de Internet: www.ezag.de ISIN: DE0005659700 WKN: 565970 Indices: SDAX, Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1773021
End of Announcement EQS News Service

1773021 14-Nov-2023 CET/CEST